Zydus receives tentative approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
Cipla has received 8 inspectional observations in Form 483
Sirolimus Tablets had annual sales of USD 69 million in the United States (IQVIA MAT Dec. 2022)
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
Themis will market this drug with the brand name REMITHEM.
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Bosentan Tablets for Oral Suspension had annual sales of USD 16 mn in the United States (IQVIA MAT Dec. 2022)
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
Thermo Fisher and Celltrio bring first-in-kind automation platform to address critical scale-up challenges in biotherapeutics RoboCell cell line automation platform
Subscribe To Our Newsletter & Stay Updated